TradingHolo

The whole market. One view. Market data from our own platform. Not investment advice. Prices in listing currency with AED alongside; market cap in USD. Live = streaming now; Delayed 15 min where the exchange requires it; At close = last official close.

News Calendar Economy IPOs ETFs Account

⌂Home ◈Markets ▦Screener 📈Tools ◎Portfolio

Skip to content

DFM General5,851.39−0.27%FTSE ADX9,783.24−0.26%TASI10,123.62−0.65%QE Index8,632.66−0.01%S&P 5007,690.73+0.41%Nasdaq 10029,529.34+1.17%Nifty 5022,888.95−1.11%Sensex73,852.90−1.17%KSE-100165,966.09−0.27%DFM:EMIRATESNBDAED 31.50−0.25%ADX:IHCAED 352.00−0.17%SAU:2222SAR 25.80+0.00%DSMD:QNBKQAR 15.66+2.29%NAS:NVDA$217.09+1.38%NYSE:TSM$420.22+1.84%NSE:RELIANCE₹1,202.00−0.76%KAR:OGDCRs 299.47+0.12%Gold$4,135.60−0.13%Brent$109.39+0.16%BTC$81,642.47−0.24%ETH$2,395.06−0.42%DFM General5,851.39−0.27%FTSE ADX9,783.24−0.26%TASI10,123.62−0.65%QE Index8,632.66−0.01%S&P 5007,690.73+0.41%Nasdaq 10029,529.34+1.17%Nifty 5022,888.95−1.11%Sensex73,852.90−1.17%KSE-100165,966.09−0.27%DFM:EMIRATESNBDAED 31.50−0.25%ADX:IHCAED 352.00−0.17%SAU:2222SAR 25.80+0.00%DSMD:QNBKQAR 15.66+2.29%NAS:NVDA$217.09+1.38%NYSE:TSM$420.22+1.84%NSE:RELIANCE₹1,202.00−0.76%KAR:OGDCRs 299.47+0.12%Gold$4,135.60−0.13%Brent$109.39+0.16%BTC$81,642.47−0.24%ETH$2,395.06−0.42%

Stock markets

🇦🇪UAEDFM · ADX · DFM GeneralClosed 🇸🇦Saudi ArabiaTadawul · TASIClosed 🇶🇦QatarQSE · QE GeneralClosed 🇺🇸United StatesNasdaq · NYSE · S&P 500Closed 🇮🇳IndiaNSE · BSE · Nifty 50Closed 🇵🇰PakistanPSX · KSE-100Closed

Other assets

₿CryptoRanked by volume · 24/7 🥇Gold, FX & economyDubai gold, AED crosses, rates ◫ETFsIndex, sector and gold funds

Explore

▦Market mapEvery market as a heatmap 📅Calendar & IPOsEarnings, dividends, listings, releases ⌁Options flow · Ownership · PoliticsUS filings and tapes

⚲Stock screenerAll six markets, one row per company ★Ready-made screensStarting points with a point of view 📁My saved screensSaved rules with alerts on new matches ⇄CompareUp to five, side by side

📈ChartingDrawings, indicators, replay ▶Strategy MakerWrite a rule, test it on history ⇄CompareSide by side 🔔AlertsPrice, earnings, screens, strategies

⌕

Sign in Create account👤

AnaptysBio Inc · Overview · TradingHolo

Markets › United States › NAS › ANAB

A

AnaptysBio Inc

NAS:ANABHealthcareCBOEFTSE:MRUTNASDAQ:NBI

$49.24+5.64%At closeAt close · Tue 20 Oct · ≈ AED 180.83 · Market cap $1.47B · Next earnings Tue 10 Nov

🔔 Alert▶ Test a strategy

Overview Chart Financials Valuation Forecasts Dividends Ownership Options Shorts News Profile

1D

+5.6%

1M

−10.8%

3M

−8.4%

6M

−3.4%

1Y

+114.7%

Why it's moving today

AnaptysBio Shares Gain on FDA Approval for Rectal Cancer Drug

Dow Jones Newswires · Mon 19 Oct

✦ This week in three lines

No written digest yet for ANAB. The figures on this page are the source when one is written.

Financials

USD millions · annual5Y CAGR +25.6%

Valuation

P/E vs sector−111.2× vs −1.7×

Price / Book vs sector39.6× vs 2.0×

Price / Sales vs sector6.3× vs 3.9×

Price / Free cash flow vs sector75.1× vs −1.6×

Forecasts

7 buy0 hold0 sell7 analysts

Average target$0.0000 −100.0%

Analysts0

EPS surprises, last 86 beats

Dividends

Yield0.0%

Annual payout—

Payout ratio0.0%

Next ex-date—

Years of growth—

Latest news

All ANAB news →

DOAnaptysBio Shares Gain on FDA Approval for Rectal Cancer Drug

Dow Jones Newswires · 7 h ago

GLJemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer

GlobeNewswire · 8 h ago

Key facts

At close · Tue 20 Oct

Market cap (USD)$1.47B

P/E−111.2×

Dividend yield0.0%

52-week range$20.18 – $72.36

Avg volume (20d)574,245

Shares outstanding29,895,200

Beta0.40

Short interest18.8% of float

Next earningsTue 10 Nov

Radar Score

55

Value41

Quality69

Momentum65

Income45

Peer percentile within United States Healthcare0–100 · null when more than one input is missing

About

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of…

SectorHealthcare

IndustryNormal

ExchangeNAS

Peers

LLNYSE:LLYEli Lilly and Co · 🇺🇸 NYSE

57.3×−1.33%

JNNYSE:JNJJohnson & Johnson · 🇺🇸 NYSE

23.0×−0.69%

ABNYSE:ABBVAbbVie Inc · 🇺🇸 NYSE

119.3×−0.96%

UNNYSE:UNHUnitedHealth Group Inc · 🇺🇸 NYSE

29.9×+1.36%